




RealRate

PHARMACEUTICAL 2018

Bellerophon Therapeutics Inc.
Rank 299 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

Bellerophon Therapeutics Inc. Rank 299 of 349

The relative strengths and weaknesses of Bellerophon Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellerophon Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 179% points. The greatest weakness of Bellerophon Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 263% points.

The company's Economic Capital Ratio, given in the ranking table, is -592%, being 314% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	35,580
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,079
Liabilities, Non-Current	0
Other Assets	204
Other Compr. Net Income	-4.0
Other Expenses	30,403
Other Liabilities	32,325
Other Net Income	184
Property and Equipment	1,026
Research and Development	17,854
Revenues	0
Selling, General and Administrative Expense	6,745

Output Variable	Value in 1000 USD
Assets	36,810
Liabilities	39,404
Expenses	55,002
Stockholders Equity	-2,594
Net Income	-54,818
Comprehensive Net Income	-54,820
Economic Capital Ratio	-592%

